Chemicals and Drugs
Altretamine
Altretamine
A hexamethyl-2,4,6-triamine derivative of 1,3,5-triazine.

Disposition and metabolism of pentamethylmelamine and hexamethylmelamine in rabbits and humans. (1/29)

The disposition and metabolism of pentamethylmelamine (PMM) and hexamethylmelamine (HMM) were studied in the rabbit, and the disposition of PMM was studied in humans. Parent compound and metabolites were identified by thin-layer chromatography, gas chromatography, and gas chromatography/mass spectrometry analyses. Plasma elimination in both species following i.v. administration of each drug was best described by a two-compartment open model. Both compounds were extensively demethylated with less than 1% of the total dose administered recovered in the urine over 24 hr. The areas under the plasma time-concentration curves of PMM and HMM following p.o. administration to rabbits were 5 and 25% of the areas following i.v. administration. Gastrointestinal absorption was rapid and efficient with 75 to 89% of drug equivalents recoverable in the urine after p.o. administration of [ring-14C]PMM or [ring-14C]HMM to rabbits. Reduced bioavailability of PMM and HMM p.o. appears to be a consequence of rapid metabolism presumably in the liver.  (+info)

Recurrent ovarian cancer: how important is it to treat to disease progression? (2/29)

Ovarian cancer is increasingly recognized as a chronic disease whose treatment is often characterized by administration of multiple, sequential active agents, each of which may or may not be accompanied by a tumor response. Despite the large proportion of patients who relapse and undergo longer-term treatment, the question of optimal treatment duration has not been fully addressed to date. For patients who progress on therapy, the answer is straightforward: they are switched to another active agent, presumably having a different mechanism of action from previous therapies with, ideally, limited overlapping toxicities. However, for patients who remain in partial response or who have stable disease, the answer is less apparent and less clear. The majority of oncologists believe that treatment beyond 6 cycles of a given therapy does not provide any additional benefit to patients. There are some data to support that treatment strategy. However, with the advent of new, less toxic agents, treatment to progression should be further explored. Agents that are potentially well suited for extended treatment intervals may include such properties as absence of cumulative toxicity, non-cross-resistance, positive benefit on quality of life, and convenient schedule. A number of active agents in ovarian cancer (platinum, paclitaxel, topotecan, liposomal doxorubicin, docetaxel, gemcitabine, and etoposide) will be reviewed in the context of what is known about cumulative toxicity, potential adverse effects on patients' quality of life, and evidence addressing the potential benefits of longer-term treatment.  (+info)

Pretreatment CA-125 and risk of relapse in advanced ovarian cancer. (3/29)

PURPOSE: A previous report suggested the nadir serum CA-125 level within the group of patients with ovarian cancer who achieved normalization of CA-125 accurately defined the risk of relapse. Using similar CA-125 subgroups, we sought to determine if the baseline CA-125 level before initiation of maintenance chemotherapy in women achieving a clinically-defined complete response to primary chemotherapy would be of prognostic value. PATIENTS AND METHODS: Patients included in this retrospective analysis had been treated on one of two previously reported trials of maintenance chemotherapy (three v 12-monthly cycles of paclitaxel; oral altretamine), with a baseline CA-125 level of < or = 35 u/mL. Progression-free survival (PFS) from study entry was analyzed by the Cox regression model. RESULTS: The distribution of premaintenance baseline CA-125 levels for the 384 patients was 58%, 34%, and 8% for values of (A) < or = 10 u/mL, (B) 11 to 20 u/mL, and (C) 21 to 35 u/mL, respectively. The baseline CA-125 was highly statistically significant, either as a categoric variable (P < .001) or as a continuous variable (P < .0001). Median PFS was 24 months, 17 months, and 7 months for groups (A), (B), and (C), respectively. There was no evidence the CA-125 effect differed by trial or treatment in an interaction analysis (P = .70). CONCLUSION: The baseline CA-125 level before initiation of maintenance chemotherapy strongly predicts the risk of subsequent relapse. Patients with premaintenance baseline CA-125 values < or = 10 u/mL have a superior PFS compared with higher levels in the normal CA-125 range.  (+info)

Relationship between frailty and cognitive decline in older Mexican Americans. (4/29)

 (+info)

Subrenal capsule assay in selection of chemotherapy after operation for recurrent ovarian cancer. (5/29)

Forty-six patients with recurrent ovarian cancer were reoperated, and cancer samples for the subrenal capsule assay (SRCA) were collected from 23 of them, whereas this test was not done in the remaining 23 control patients. The SRCA was evaluable in 22 cases (96%). Taken together, no significant difference appeared in the 3 years' survival figures between the groups: seven of 22 patients (32%) with the evaluable SRCA and six of 23 control patients (26%) were alive. However, a further analysis of the data revealed that the SRCA guided the selection of chemotherapy only in 15 patients, whereas tumour samples were resistant to all cytostatics tested in six cases and toxic side-effects limited the clinical application of the test results in the remaining one case. Four of the 11 patients (36%) whose further chemotherapy was strictly chosen based on the SRCA and seven of the 24 patients (29%) whose treatment was based on physician's choice survived at least 3 years. Our conclusion is that the SRCA is of limited value in the selection of second-line chemotherapy in recurrent ovarian cancer.  (+info)

Long-term follow-up and prognostic factor analysis in advanced ovarian carcinoma: the Gynecologic Oncology Group experience. (6/29)

Long-term follow-up was obtained on 726 women with advanced ovarian carcinoma (suboptimal stage III and stage IV) who had received primary chemotherapy on two Gynecologic Oncology Group (GOG) protocols between 1976 and 1982. The first study compared melphalan alone versus melphalan plus hexamethylmelamine versus cyclophosphamide plus doxorubicin (CA). The second study evaluated the same CA regimen with or without cisplatin. Eligibility for the two studies was the same. At last contact, 76 patients were alive. In a multivariate analysis, cell type other than clear cell or mucinous, cisplatin-based treatment, good performance status, younger age, lower stage, clinically nonmeasurable disease, smaller residual tumor volume, and absence of ascites were favorable characteristics for overall survival (P less than .05). Second-look laparotomy was negative significantly more often among those with endometrioid tumors; there were no negative second-look laparotomies among those with mucinous or clear cell tumors. There were 30 patients with suboptimal stage III disease who had a negative second-look laparotomy; 18 (60%) have experienced recurrence, and 13 (43%) have died. Although cisplatin treatment was beneficial, new treatments are clearly needed.  (+info)

Hexamethylmelamine as consolidation treatment for patients with advanced epithelial ovarian cancer in complete response after first-line chemotherapy. (7/29)

 (+info)

Prognostic factors in advanced epithelial ovarian cancer. (Gruppo Interregionale Cooperativo di Oncologia Ginecologica (GICOG)). (8/29)

The data on 914 patients enrolled in four randomised trials in advanced ovarian cancer, consecutively conducted by the same cooperative group between 1978 and 1986, were analysed with the aims of: (1) determining the impact of selected prognostic variables on survival; (2) finding, from the interaction of favourable prognostic factors and treatment, an approximate estimate of the magnitude of the survival advantage associated with the use of platinum-based combination chemotherapy. The overall 3-year survival in this series of patients is twice that reported historically (22%; 95% CL 18.7-25.4). The proportional hazard regression model was used to perform the analysis on survival. Residual tumour size, age, FIGO stage and cell type were all independent determinants of survival. Differences in survival from the various prognostic groups were impressive with 5-year survival rates ranging from 7 to 62%. However, these differences were not qualitative (i.e. the kinetics of survival were similar for the best and the worst groups) suggesting that current prognostic factors are of little use for selecting 'biologically' different sub-populations. Platinum-based regimens were associated to an overall prolonged median survival, but this benefit was not observable in the subgroup with most favourable prognosis (less than 2 cm residual tumour size). The implications of these observations for clinical research and ovarian cancer patients care are discussed.  (+info)

Hexamethylmelamine-A new drug with activity in solid tumors<...
TY - JOUR. T1 - Hexamethylmelamine-A new drug with activity in solid tumors. AU - Blum, Ronald H.. AU - Livingston, Robert B.. AU - Carter, Stephen K.. PY - 1973/3. Y1 - 1973/3. N2 - Hexamethylmelamine (NSC 13875) is a iriazine that has completed phase I-II trials under the sponsorship of the Division of Cancer Treatment, National Cancer Institute. It was selected for clinical trial based on superior activity against the Walker 256 carcinosarcoma. In the clinical trials reported, the dose schedules used were 4-15 mg/kd/d for 21-90 days. Dose limiting toxicity was gastrointestinal. Also seen were leukopenia, thrombocylopenia, and central nervous system toxicity. The overall response rate in 784 evaluable patients was 17%. Greater than 20% response rates were seen in the following tumor types: small cell (oat) carcinoma of the lung, ovarian adenocarcinoma, lymphoma, and breast cancer. Further controlled clinical trials in certain tumor types are warranted.. AB - Hexamethylmelamine (NSC 13875) is a ...
https://arizona.pure.elsevier.com/en/publications/hexamethylmelamine-a-new-drug-with-activity-in-solid-tumors
Altretamine and Etoposide in Treating Patients With HIV-Related Cancer - Full Text View - ClinicalTrials.govAltretamine and Etoposide in Treating Patients With HIV-Related Cancer - Full Text View - ClinicalTrials.gov
DISEASE CHARACTERISTICS: Documented HIV antibody positive Histologically confirmed, by biopsy, non-Hodgkins lymphoma that is in complete remission or stable/partial remission for a minimal period of one month And/or Histologically confirmed, by biopsy, Kaposis sarcoma without stable disease. PATIENT CHARACTERISTICS: Age: 18 and over Performance status: Karnofsky 60-100% Hematopoietic: Absolute neutrophil count at least 500/mm3 Platelet count greater than 25,000/mm3 (unless secondary to lymphoma) Hepatic: Transaminases less than 5 times upper limit of normal AND Bilirubin less than 2.0, unless secondary to lymphoma Renal: Creatinine less than 2.0 mg/dL OR Creatinine clearance at least 60 mL/min Dose reduction of 21% if creatinine clearance 10-50 mL/min Dose reduction of 50% if creatinine clearance less than 10 mL/min Cardiovascular: No active cardiac arrhythmia or angina Pulmonary: Must exclude Pneumocystis carinii pneumonia if there is any suspicion of infection Other: No uncontrolled ...
https://clinicaltrials.gov/show/NCT00002936?order=72
Altretamine capsulesAltretamine capsules
Visit your doctor for checks on your progress.. This drug may make you feel generally unwell. This is not uncommon, as chemotherapy can affect healthy cells as well as cancer cells. Report any side effects. Continue your course of treatment even though you feel ill unless your doctor tells you to stop.. Call your doctor or health care professional for advice if you get a fever, chills or sore throat, or other symptoms of a cold or flu. Do not treat yourself. This drug decreases your bodys ability to fight infections. Try to avoid being around people who are sick.. This medicine may increase your risk to bruise or bleed. Call your doctor or health care professional if you notice any unusual bleeding.. Be careful brushing and flossing your teeth or using a toothpick because you may get an infection or bleed more easily. If you have any dental work done, tell your dentist you are receiving this medicine.. Avoid taking products that contain aspirin, acetaminophen, ibuprofen, naproxen, or ketoprofen ...
http://healthlibrary.brighamandwomens.org/Library/DiseasesConditions/Adult/121,547
Altretamine capsulesAltretamine capsules
Visit your doctor for checks on your progress.. This drug may make you feel generally unwell. This is not uncommon, as chemotherapy can affect healthy cells as well as cancer cells. Report any side effects. Continue your course of treatment even though you feel ill unless your doctor tells you to stop.. Call your doctor or health care professional for advice if you get a fever, chills or sore throat, or other symptoms of a cold or flu. Do not treat yourself. This drug decreases your bodys ability to fight infections. Try to avoid being around people who are sick.. This medicine may increase your risk to bruise or bleed. Call your doctor or health care professional if you notice any unusual bleeding.. Be careful brushing and flossing your teeth or using a toothpick because you may get an infection or bleed more easily. If you have any dental work done, tell your dentist you are receiving this medicine.. Avoid taking products that contain aspirin, acetaminophen, ibuprofen, naproxen, or ketoprofen ...
https://healthlibrary.vidanthealth.com/Library/DiseasesConditions/Adult/Men/121,547
Altretamine capsules
Visit your doctor for checks on your progress.. This drug may make you feel generally unwell. This is not uncommon, as chemotherapy can affect healthy cells as well as cancer cells. Report any side effects. Continue your course of treatment even though you feel ill unless your doctor tells you to stop.. Call your doctor or health care professional for advice if you get a fever, chills or sore throat, or other symptoms of a cold or flu. Do not treat yourself. This drug decreases your bodys ability to fight infections. Try to avoid being around people who are sick.. This medicine may increase your risk to bruise or bleed. Call your doctor or health care professional if you notice any unusual bleeding.. Be careful brushing and flossing your teeth or using a toothpick because you may get an infection or bleed more easily. If you have any dental work done, tell your dentist you are receiving this medicine.. Avoid taking products that contain aspirin, acetaminophen, ibuprofen, naproxen, or ketoprofen ...
http://healthlibrary.lomalindahealth.org/Conditions/Cancer/121,547
Cisplatin and etoposide as second-line chemotherapy in patients with small cell lung cancer<...
TY - JOUR. T1 - Cisplatin and etoposide as second-line chemotherapy in patients with small cell lung cancer. AU - Figoli, Franco. AU - Veronesi, Andrea. AU - Ardizzoni, Andrea. AU - Canobbio, Luciano. AU - Bruschi, Gioia. AU - Mazza, Francesco. AU - Zagonel, Vittorina. AU - Lo Re, Giovanni. AU - Rosso, Riccardo. AU - Monfardini, Silvio. PY - 1988. Y1 - 1988. N2 - Twenty-seven evaluable patients with small cell lung cancer (SCLC) resistant to, or relapsed after induction combination chemotherapy (CT) were treated with etoposide (VPJ6) plus cisplatin (DDP). Previous treatment was: alternating CT with cyclophosphamide (C), adriamycin (A), methotrexate (M), procarbazine (P) (CAMP)/VP16, BCNU (B), hexamethylmelamine (H) (VP16BH) in 16 patients; C, A, vincristine (CAV) in 6 patients; C, A, and VP16 (CAVP16) in 5 patients. We observed 2 (7% complete responses (CR) and 9 (33% partial responses (PR). Duration of CRs was 8 and 14 weeks, respectively. PRs lasted a median of 22 weeks (range 16-44). Seven of ...
https://moh-it.pure.elsevier.com/en/publications/cisplatin-and-etoposide-as-second-line-chemotherapy-in-patients-w
Chemo bandanas - Answers on HealthTapChemo bandanas - Answers on HealthTap
Doctors give unbiased, helpful information on indications, contra-indications, benefits, and complications: Dr. Romero on chemo bandanas: Choosing chemo depends on many factors, so only your doctor can decide what might work for you. Drugs you havent mentioned include altretamine, capecitabine, cytoxan, (cyclophosphamide) vinorelbine, ifosfamide, etoposide, and irinotecan. There are also several hormonal agents. And a clinical trial might be an option. Check out www.Cancer.Gov for more info. And good luck.
https://www.healthtap.com/topics/chemo-bandanas
4-O- substituted isoindoline derivatives and compositions comprising and methods of using the same - Patent application4-O- substituted isoindoline derivatives and compositions comprising and methods of using the same - Patent application
0108]Other second agents include, but are not limited to: 20-epi-1,25 dihydroxyvitamin D3; 5-ethynyluracil; abiraterone; aclarubicin; acylfulvene; adecypenol; adozelesin; aldesleukin; ALL-TK antagonists; altretamine; ambamustine; amidox; amifostine; aminolevulinic acid; amrubicin; amsacrine; anagrelide; anastrozole; andrographolide; angiogenesis inhibitors; antagonist D; antagonist G; antarelix; anti-dorsalizing morphogenetic protein-1; antiandrogen, prostatic carcinoma; antiestrogen; antineoplaston; antisense oligonucleotides; aphidicolin glycinate; apoptosis gene modulators; apoptosis regulators; apurinic acid; ara-CDP-DL-PTBA; arginine deaminase; asulacrine; atamestane; atrimustine; axinastatin 1; axinastatin 2; axinastatin 3; azasetron; azatoxin; azatyrosine; baccatin III derivatives; balanol; batimastat; BCR/ABL antagonists; benzochlorins; benzoylstaurosporine; beta lactam derivatives; beta-alethine; betaclamycin B; betulinic acid; bFGF inhibitor; bicalutamide; bisantrene; ...
http://www.patentsencyclopedia.com/app/20090004209
METHODS FOR TREATMENT OF MULTIPLE MYELOMA USING 3-(4-AMINO-1-OXO-1,3-DIHYDROISOINDOL-2-YL)-PIPERIDINE-2,6-DIONE IN COMBINATION...METHODS FOR TREATMENT OF MULTIPLE MYELOMA USING 3-(4-AMINO-1-OXO-1,3-DIHYDROISOINDOL-2-YL)-PIPERIDINE-2,6-DIONE IN COMBINATION...
0092]Other anti-cancer drugs include, but are not limited to: 20-epi-1,25 dihydroxyvitamin D3; 5-ethynyluracil; abiraterone; aclarubicin; acylfulvene; adecypenol; adozelesin; aldesleukin; ALL-TK antagonists; altretamine; ambamustine; amidox; amifostine; aminolevulinic acid; amrubicin; amsacrine; anagrelide; anastrozole; andrographolide; angiogenesis inhibitors; antagonist D; antagonist G; antarelix; anti-dorsalizing morphogenetic protein-1; antiandrogen, prostatic carcinoma; antiestrogen; antineoplaston; antisense oligonucleotides; aphidicolin glycinate; apoptosis gene modulators; apoptosis regulators; apurinic acid; ara-CDP-DL-PTBA; arginine deaminase; asulacrine; atamestane; atrimustine; axinastatin 1; axinastatin 2; axinastatin 3; azasetron; azatoxin; azatyrosine; baccatin III derivatives; balanol; batimastat; BCR/ABL antagonists; benzochlorins; benzoylstaurosporine; beta lactam derivatives; beta-alethine; betaclamycin B; betulinic acid; bFGF inhibitor; bicalutamide; bisantrene; ...
http://www.patentsencyclopedia.com/app/20100093683
Four-Drug Combination Treatment in Hiv-Infected Subjects Failing Therapy With Antiretroviral Regimens - Full Text View -...Four-Drug Combination Treatment in Hiv-Infected Subjects Failing Therapy With Antiretroviral Regimens - Full Text View -...
This is a 48 week study for HIV-infected patients who have failed several regimens including PIs, NNRTs and NRTIs. Patients will be randomly selected to be in 1 of 4 groups. Three of the 4 groups will contain capravirine in different doses combined with Kaletra and nucleosides and one of the groups will be a combination of Kaletra and nucleosides without the capravirine ...
https://clinicaltrials.gov/show/NCT00052117?order=575
E4897 - Archived Educational Materials - ECOG-ACRINE4897 - Archived Educational Materials - ECOG-ACRIN
Title. Comparing the Effectiveness of Different Drug Combinations for Advanced Cancer of the Urothelium Which Cannot Be Controlled With Surgery (A Phase III Trial). Sponsor. Eastern Cooperative Oncology Group through the NCI-sponsored Cancer Cooperative Group Program. Purpose of the Study. To slow, stop or decrease the growth of cancer of the urothelium and to compare and evaluate the effectiveness of the two drug treatments. The two treatments were; 1) a Two-Drug (paclitaxel and carboplatin) Combination Chemotherapy, and 2) a Four-Drug (methotrexate, vinblastine, asplatin, doxorubin) Combination Chemotherapy. The urothelium is the lining of the kidney, ureter, bladder, or lining of the urinary tract.. Results. The study did not show one treatment to be more beneficial than the other. Of patients receiving the four-drug combination, 12.8 percent experienced a complete response rate (no detectable cancer remaining) and 23.1 percent experienced a decrease in the size or extent of their cancer ...
http://ecog-acrin.org/clinical-trials/E4897-archived-educational-materials
The Challenges of Risk Perception and Infectious Disease Response: Counteracting Inaccurate Risk Perception | Scowcroft...The Challenges of Risk Perception and Infectious Disease Response: Counteracting Inaccurate Risk Perception | Scowcroft...
The Challenges of Risk Perception and Infectious Disease Response: Counteracting Inaccurate Risk Perception is a research paper published by the Scowcroft Institute of International Affairs at the Bush School of Government and Public Service at Texas A&M University.
http://bush.tamu.edu/scowcroft/papers/crudo/
Horton, C.Horton, C.
Four-drug combination chemotherapy (methotrexate, cyclophosphamide, hexamethylmelamine, and CCNU) for non-small cell bronchogenic carcinoma: A cancer and leukemia group B study. Journal of Clinical Oncology. 1983 ...
http://vivo.med.cornell.edu/display/person527955
Why are fixed dose combinations of antibiotics generally not a good idea? - 2018 - ReActWhy are fixed dose combinations of antibiotics generally not a good idea? - 2018 - ReAct
TB, HIV and Malaria are three major infectious diseases of global health importance where predefined combinations of drugs is standard recommendation for treatment. For example, for drug sensitive TB the recommended treatment is a four-drug combination of Isoniazid, Rifampicin, Pyrazinamide and Ethambutol for two months, followed by 4 months of Isoniazid and Rifampicin (2HRZE/4HR). For multidrug-resistant TB, recommendations include six drugs for 4-6 months followed by four drugs during 5 months. Similarly, HIV is treated with a combination of four antiretrovirals and Malaria is treated with combinations with Artemisin. In these cases fixed dose combinations are recommended in the World Health Organization (WHO) treatment guidelines, and several generics have been pre-qualified by WHO as well.. As the treatment periods are long with several drugs, recommendations include using fixed dose combinations or daily dose bags to improve compliance to treatment. This has indeed been a very important ...
https://www.reactgroup.org/news-and-views/news-and-opinions/year-2018/why-are-fixed-dose-combinations-of-antibiotics-generally-not-a-good-idea/
Animal Disease Response Training - Ohio Farm BureauAnimal Disease Response Training - Ohio Farm Bureau
Animal Disease Response Training provides the critical information needed to minimize the affects of an outbreak on your community. Responders to whom this
https://ofbf.org/events/animal-disease-response-training-7/
The prognostic impact of EphB2/B4 expression on patients with advanced ovarian carcinoma. - PubMed - NCBIThe prognostic impact of EphB2/B4 expression on patients with advanced ovarian carcinoma. - PubMed - NCBI
PubMed comprises more than 30 million citations for biomedical literature from MEDLINE, life science journals, and online books. Citations may include links to full-text content from PubMed Central and publisher web sites.
https://www.ncbi.nlm.nih.gov/pubmed/16499955?dopt=Abstract
General | Regulation of human neutrophil-mediated cartilage proteoglycan degradationGeneral | Regulation of human neutrophil-mediated cartilage proteoglycan degradation
The level of an individual protein in cells treated with combinations of drugs is best explained by simple linear superposition of the protein levels in response to single drugs. and protease inhibitors used to treat HIV contamination4 and the four-drug combination comprising DNA-damaging brokers a microtubule disruptor and a corticosteroid (cyclophosphamide doxorubicin vincristine and prednisone together known as CHOP) used to treat non-Hodgkins lymphoma5. Variations on these treatments exist SCH-527123 that add even more drugs to the mix. Given this SCH-527123 pattern one may ask: what is the most effective drug combination complexity and how will we know when we get there? In nature a bacterial endosymbiont growing around the antennae of certain wasp species releases a cocktail of nine different antibiotic compounds that together protect growing wasp larvae from a broad range of fungal and bacterial pathogens6. This suggests that we have much to SCH-527123 go before achieving the same ...
https://acmbcb.org/category/general/
March | 2017 | Regulation of human neutrophil-mediated cartilage proteoglycan degradationMarch | 2017 | Regulation of human neutrophil-mediated cartilage proteoglycan degradation
The level of an individual protein in cells treated with combinations of drugs is best explained by simple linear superposition of the protein levels in response to single drugs. and protease inhibitors used to treat HIV contamination4 and the four-drug combination comprising DNA-damaging brokers a microtubule disruptor and a corticosteroid (cyclophosphamide doxorubicin vincristine and prednisone together known as CHOP) used to treat non-Hodgkins lymphoma5. Variations on these treatments exist SCH-527123 that add even more drugs to the mix. Given this SCH-527123 pattern one may ask: what is the most effective drug combination complexity and how will we know when we get there? In nature a bacterial endosymbiont growing around the antennae of certain wasp species releases a cocktail of nine different antibiotic compounds that together protect growing wasp larvae from a broad range of fungal and bacterial pathogens6. This suggests that we have much to SCH-527123 go before achieving the same ...
http://acmbcb.org/2017/03/
Development of an Aquatic Emergency Animal Disease Response Agreement - Animal Health AustraliaDevelopment of an Aquatic Emergency Animal Disease Response Agreement - Animal Health Australia
In October 2014 AHA commenced management of a new, Department of Agriculture and Water Resources funded, four year project dedicated to the development of a formal industry-government aquatic emergency animal disease response agreement.. While Australia has long-standing joint industry-government arrangements in place for responses to livestock emergency diseases and emergency plant pests and diseases, until now, theres been nothing formally in place for responding to emergency disease outbreaks affecting aquatic animals and the industries that rely on them.. Aquatic animal industries as well as governments have long recognised this as a significant gap in our national preparedness and response tackle box. Previous work on developing formal industry-Government emergency aquatic animal disease response arrangements focussed on the abalone sector (aquaculture and wild capture). This project aims to build on previous efforts and eventually cover most aquatic animal industries.. An Aquatic Deed ...
https://www.animalhealthaustralia.com.au/what-we-do/emergency-animal-disease/development-emergency-aquatic-animal-disease-response-arrangements/
High-intensity Focused Ultrasound (HIFU) As Salvage Therapy For Radio-recurrent Prostate Cancer: Predictors Of Disease Response...High-intensity Focused Ultrasound (HIFU) As Salvage Therapy For Radio-recurrent Prostate Cancer: Predictors Of Disease Response...
Vol. 43 (x): 2017 November 11. doi: 10.1590/S1677-5538.IBJU.2017.0025 ORIGINAL ARTICLE Shawn Dason 1, Nathan C. Wong 1, Christopher B. Allard 1,
http://www.intbrazjurol.com.br/original-article/high-intensity-focused-ultrasound-hifu-as-salvage-therapy-for-radio-recurrent-prostate-cancer-predictors-of-disease-response/
Kansas running animal disease response exercise - Washington TimesKansas running animal disease response exercise - Washington Times
State and local officials in four Kansas counties are conducting an exercise to practice the states plan to respond to a foreign animal disease.
https://www.washingtontimes.com/news/2014/sep/22/kansas-running-animal-disease-response-exercise/
Approves Gileads four-drug HIV treatment - tribunedigital-chicagotribuneApproves Gileads four-drug HIV treatment - tribunedigital-chicagotribune
* Gileads once-daily quad pill to be sold as Stribild * Gilead to conduct further studies on safety, drug interactions * Shares unchanged after hours (Adds analyst comment, label information,
http://articles.chicagotribune.com/2012-08-27/business/sns-rt-gilead-hiv-update-2l1e8jriix-20120827_1_quad-pill-emtricitabine-and-tenofovir-complera
Correlation of p53 immunostaining in primary and residual ovarian cancer at the time of positive second-look laparotomy and its...
TY - JOUR. T1 - Correlation of p53 immunostaining in primary and residual ovarian cancer at the time of positive second-look laparotomy and its prognostic role. T2 - A Southwest Oncology Group ancillary study. AU - Hawes, Debra. AU - Liu, P. Y.. AU - Muggia, Franco M.. AU - Wilczynski, Sharon. AU - Cote, Richard. AU - Felix, Juan. AU - Terada, Keith. AU - Belt, Robert J.. AU - Alberts, David S. PY - 2002. Y1 - 2002. N2 - Objective. The objective of this study was to verify the correlation between p53 immunostaining at initial diagnosis and at positive reassessment after completing platinum-based chemotherapy and to assess prognostic differences between patients whose tumors display positive immunostaining versus those that have negative immunostaining at such reassessment. Methods. This study made use of samples from patients entered into a prospective randomized study of the Southwest Oncology Group (SWOG 8835) that treated patients with minimal residual disease at second-look laparotomy with ...
https://arizona.pure.elsevier.com/en/publications/correlation-of-p53-immunostaining-in-primary-and-residual-ovarian
Correlation of p53 immunostaining in primary and residual ovarian cancer at the time of positive second-look laparotomy and its...
TY - JOUR. T1 - Correlation of p53 immunostaining in primary and residual ovarian cancer at the time of positive second-look laparotomy and its prognostic role. T2 - A Southwest Oncology Group ancillary study. AU - Hawes, Debra. AU - Liu, P. Y.. AU - Muggia, Franco M.. AU - Wilczynski, Sharon. AU - Cote, Richard J. AU - Felix, Juan. AU - Terada, Keith. AU - Belt, Robert J.. AU - Alberts, David S.. PY - 2002/12/1. Y1 - 2002/12/1. N2 - Objective. The objective of this study was to verify the correlation between p53 immunostaining at initial diagnosis and at positive reassessment after completing platinum-based chemotherapy and to assess prognostic differences between patients whose tumors display positive immunostaining versus those that have negative immunostaining at such reassessment. Methods. This study made use of samples from patients entered into a prospective randomized study of the Southwest Oncology Group (SWOG 8835) that treated patients with minimal residual disease at second-look ...
https://miami.pure.elsevier.com/en/publications/correlation-of-p53-immunostaining-in-primary-and-residual-ovarian
Influence of secondary cytoreduction at the time of second-look laparotomy on the survival of patients with epithelial ovarian...Influence of secondary cytoreduction at the time of second-look laparotomy on the survival of patients with epithelial ovarian...
Influence of secondary cytoreduction at the time of second-look laparotomy on the survival of patients with epithelial ovarian carcinoma Academic Article Article ...
http://vivo.med.cornell.edu/display/pubid0024418443
Drug information handbook for oncology : a complete guide to combination chemotherapy regimens (Book, 2013) [WorldCat.org]Drug information handbook for oncology : a complete guide to combination chemotherapy regimens (Book, 2013) [WorldCat.org]
Get this from a library! Drug information handbook for oncology : a complete guide to combination chemotherapy regimens. [Diedra L Bragalone; Lexi-Comp, Inc.;]
http://www.worldcat.org/title/drug-information-handbook-for-oncology-a-complete-guide-to-combination-chemotherapy-regimens/oclc/814455502
GIS online training course «The use of GIS in animal disease response»GIS online training course «The use of GIS in animal disease response»
The course presents an empirical approach to implement a GIS project and provides an introduction to QGIS. Availabile from 13 february 2018 to 12 febbraio 2019. Free of charge. Endorsed by the OIE.
https://www.izsvenezie.com/online-training-course-gis-oie/
Drug combo effective against recurrent ovarian cancer; New oncopig billed as advance for cancer R&D; p53 mechanism could be...Drug combo effective against recurrent ovarian cancer; New oncopig billed as advance for cancer R&D; p53 mechanism could be...
| A UCLA team found that using a combination of birinapant with a chemotherapy eliminated a population of cells responsible for recurrent ovarian cancer. Birinapant sensitizes CA125-negative cells...
https://www.fiercebiotech.com/research/drug-combo-effective-against-recurrent-ovarian-cancer-new-oncopig-billed-as-advance-for
Natural Compounds Block Autoimmune Disease Response in Diabetes and Arthritis - BioTech WeblogNatural Compounds Block Autoimmune Disease Response in Diabetes and Arthritis - BioTech Weblog
Researchers have identified lead compounds from Cuban sea anemone extract and the rue plant that may help treat autoimmune disease response in type-1 diabetes and rheumatoid arthritis. The compounds act by blocking the ion channel in autoimmune T lymphocytes and disabling these cells, while allowing other white blood cells to fight disease and infection.. In one set of tests using blood samples from type-1 diabetes patients and joint fluid from people with rheumatoid arthritis, the researchers found that both compounds suppressed the function of the autoimmune T-cells without affecting other T-cells that fight infections.. In another set of tests using rats, the compound from the rue shrub plant delayed the onset and reduced the incidence of disease in diabetic rats, while the venom compound stopped the progression of the disease and improved the joint function of rats with experimental autoimmune arthritis. In these rat tests, the compounds were nontoxic.. The study was published in the Nov. ...
http://www.biotech-weblog.com/natural-compounds-block-autoimmune-disease-response-in-diabetes-and-arthritis/
Pembrolizumab shows modest, durable response in recurrent ovarian cancerPembrolizumab shows modest, durable response in recurrent ovarian cancer
In the KEYNOTE-100 study, presented during the ASCO2020 Virtual Scientific Program, Ursula A. Matulonis, MD, of Dana Farber Cancer Institute, showed pembrolizumab had a modest but durable impact on recurrent ovarian cancer.“Pembrolizumab like other single-agent immune checkpoint inhibitors which have been studied in recurrent ovarian cancer, has modest activity in recurrent ovarian cancer.
https://www.healio.com/news/hematology-oncology/20200701/pembrolizumab-shows-modest-durable-response-in-recurrent-ovarian-cancer
CDC pilot programs boost disease response in Uganda, Vietnam | THE OUTBREAKCDC pilot programs boost disease response in Uganda, Vietnam | THE OUTBREAK
The US Centers for Disease Control and Prevention (CDC) today released details about efforts to enhance disease detection in Uganda and Vietnam that could provide a model for helping other countries protect their citizens and the wider global community from health threats. In both instances, the CDC and its partners undertook 6-month missions that focused…
https://followtheoutbreak.wordpress.com/2014/01/31/cdc-pilot-programs-boost-disease-response-in-uganda-vietnam/
SENATE BILL NO. 1421, As Amended - Idaho State LegislatureSENATE BILL NO. 1421, As Amended - Idaho State Legislature
IN THE SENATE SENATE BILL NO. 1421, As Amended BY RESOURCES AND ENVIRONMENT COMMITTEE 1 AN ACT 2 RELATING TO CLOSURES OF PUBLIC LANDS, HIGHWAYS, ROADS OR PATHS; AMENDING CHAP- 3 TER 23, TITLE 67, IDAHO CODE, BY THE ADDITION OF A NEW SECTION 67-2347A, 4 IDAHO CODE, TO REQUIRE PUBLIC COMMENTS PRIOR TO CLOSURES OF PUBLIC LANDS, 5 HIGHWAYS, ROADS OR ROADWAYS BY THE DEPARTMENT OF FISH AND GAME OR THE 6 DEPARTMENT OF LANDS UNDER CERTAIN CIRCUMSTANCES. 7 Be It Enacted by the Legislature of the State of Idaho: 8 SECTION 1. That Chapter 23, Title 67, Idaho Code, be, and the same is 9 hereby amended by the addition thereto of a NEW SECTION , to be 10 known and designated as Section 67-2347A, Idaho Code, and to read as follows: 11 67-2347A. CLOSURES OF CERTAIN STATE LANDS -- PUBLIC HEARING. Whenever the 12 Idaho department of lands or the department of fish and game is proposing to 13 close all or a portion of public land, a highway, road or other roadway which 14 has previously been open to public motor ...
https://legislature.idaho.gov/sessioninfo/1998/legislation/s1421/
Study of Platelet Derived Growth Factor Receptor (PDGFR) in Recurrent Malignant GliomasStudy of Platelet Derived Growth Factor Receptor (PDGFR) in Recurrent Malignant Gliomas
The purpose of this study is to determine the survival, disease response, and side effects of Tasigna® (nilotinib) in patients who have malignant gliom
http://www.knowcancer.com/cancer-trials/NCT01140568/
Ranitidine - WikipediaRanitidine - Wikipedia
Ranitidine was first prepared as AH19065 by John Bradshaw in the summer of 1977 in the Ware research laboratories of Allen & Hanburys, part of the Glaxo organization.[36][37] Its development was a response to the first in class histamine H2 receptor antagonist, cimetidine, developed by Sir James Black at Smith, Kline and French, and launched in the United Kingdom as Tagamet in November 1976. Both companies would eventually become merged as GlaxoSmithKline following a sequence of mergers and acquisitions starting with the integration of Allen & Hanburys Ltd and Glaxo to form Glaxo Group Research in 1979, and ultimately with the merger of Glaxo Wellcome and SmithKline Beecham in 2000. Ranitidine was the result of a rational drug-design process using what was by then a fairly refined model of the histamine H2 receptor and quantitative structure-activity relationships. Glaxo refined the model further by replacing the imidazole ring of cimetidine with a furan ring with a nitrogen-containing ...
https://en.wikipedia.org/wiki/Ranitidine
Plus itPlus it
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is an aggressive hematologic malignancy with dismal outcomes for which no standard therapy exists. We found that primary BPDCN cells were dependent on the antiapoptotic protein BCL2 and were uniformly sensitive to the BCL2 inhibitor venetoclax, as measured by direct cytotoxicity, apoptosis assays, and dynamic BH3 profiling. Animals bearing BPDCN patient-derived xenografts had disease responses and improved survival after venetoclax treatment in vivo. Finally, we report on 2 patients with relapsed/refractory BPDCN who received venetoclax off-label and experienced significant disease responses. We propose that venetoclax or other BCL2 inhibitors undergo expedited clinical evaluation in BPDCN, alone or in combination with other therapies. In addition, these data illustrate an example of precision medicine to predict treatment response using ex vivo functional assessment of primary tumor tissue, without requiring a genetic ...
http://cancerdiscovery.aacrjournals.org/content/7/2/156
Second-look operation | definition of second-look operation by Medical dictionarySecond-look operation | definition of second-look operation by Medical dictionary
Looking for online definition of second-look operation in the Medical Dictionary? second-look operation explanation free. What is second-look operation? Meaning of second-look operation medical term. What does second-look operation mean?
https://medical-dictionary.thefreedictionary.com/second-look+operation
Webcast: Recognizing and Overcoming Challenges in the Treatment of Recurrent Ovarian Cancer | Libbys H*O*P*E*
Maurie Markman, M.D. is the Vice President for Clinical Research at the University of Texas M.D. Anderson Cancer Center located in Houston, Texas. On June 6, 2008, Dr. Markman moderated an expert panel discussion entitled, Recognizing and Overcoming Challenges in the Treatment of Recurrent Ovarian Cancer. The panel discussion was recorded as a Continuing Medical…
https://libbyshope.com/2008/06/24/recognizing-and-overcoming-challenges-in-the-treatment-of-recurrent-ovarian-cancer/
IM-862 in Treating Patients With Recurrent Ovarian CancerIM-862 in Treating Patients With Recurrent Ovarian Cancer
RATIONALE: IM-862 may stop the growth of ovarian cancer by stopping blood flow to the tumor. PURPOSE: Phase I trial to study the effectiveness of IM-86
http://www.knowcancer.com/cancer-trials/NCT00003773/
Recurrent Ovarian Cancer: Understand Your Treatment OptionsRecurrent Ovarian Cancer: Understand Your Treatment Options
Thanks to targeted drugs and evolving research, women who experience recurrences of ovarian cancer have more treatment options than they did in the past..
https://www.curetoday.com/conferences/ocnc-2018/recurrent-ovarian-cancer-understand-your-treatment-options-
Zejula Approved for Recurrent Ovarian Cancer, Primary Peritoneal Cancer - MPRZejula Approved for Recurrent Ovarian Cancer, Primary Peritoneal Cancer - MPR
The Food and Drug Administration (FDA) has approved Zejula (niraparib capsules; Tesaro) for the maintenance treatment of adults with recurrent epithelial o
http://www.empr.com/news/recurrent-epithelial-fallopian-tube-cancer-zejula-niraparib/article/646795/
Ontogeny and disease responses of Langerhans-like cells in lymphoid tissues of salmonid fish | IslandScholarOntogeny and disease responses of Langerhans-like cells in lymphoid tissues of salmonid fish | IslandScholar
The ontogeny and disease responses of Langerhans-like cells within lymphoid tissues of Atlantic salmon, Salmo salar, and rainbow trout, Oncorhynchus mykiss, were investigated. These cells were studied in situ with the use of two markers: the ultrastructural presence of Birbeck-like granules and immunohistochemistry with an antibody against human langerin/CD207 that cross-reacts with salmonid tissues. The appearance of Birbeck-like granules was observed in rainbow trout at 2 weeks post-hatch (PH) Show moreThe ontogeny and disease responses of Langerhans-like cells within lymphoid tissues of Atlantic salmon, Salmo salar, and rainbow trout, Oncorhynchus mykiss, were investigated. These cells were studied in situ with the use of two markers: the ultrastructural presence of Birbeck-like granules and immunohistochemistry with an antibody against human langerin/CD207 that cross-reacts with salmonid tissues. The appearance of Birbeck-like granules was observed in rainbow trout at 2 weeks post-hatch (PH) ...
http://www.islandscholar.ca/islandora/object/ir:1005
The Experience of Being Aware of Disease Status in Women with Recurrent Ovarian Cancer: A Phenomenological Study<...
TY - JOUR. T1 - The Experience of Being Aware of Disease Status in Women with Recurrent Ovarian Cancer. T2 - A Phenomenological Study. AU - Finlayson, Catherine Scott. AU - Fu, Mei R.. AU - Squires, Allison. AU - Applebaum, Allison. AU - Van Cleave, Janet. AU - OCearbhaill, Roisin. AU - Derosa, Antonio P.. PY - 2019/3/27. Y1 - 2019/3/27. N2 - Background: Awareness of disease status has been identified as a factor in the treatment decision-making process. Women with recurrent ovarian cancer are facing the challenge of making treatment decisions throughout the disease trajectory. It is not understood how women with ovarian cancer perceive their disease and subsequently make treatment decisions. Purpose: The purpose of this phenomenological study was to understand the lived experience of women with recurrent ovarian cancer, how they understood their disease and made their treatment decisions. Methods: A qualitative design with a descriptive phenomenological method was used to conduct 2 in-depth ...
https://nyu-staging.pure.elsevier.com/en/publications/the-experience-of-being-aware-of-disease-status-in-women-with-rec-2
Gilead: Second Trial of 4-Drug AIDS Pill Meets Goal | Fox NewsGilead: Second Trial of 4-Drug AIDS Pill Meets Goal | Fox News
Gilead Sciences Incs four-drug experimental HIV pill worked as well as a regimen containing protease inhibitor Reyataz in the second pivotal trial of the drug
http://www.foxnews.com/health/2011/09/20/gilead-second-trial-4-drug-aids-pill-meets-goal.html
ViiVs Two-Drug HIV Treatment Works Well - POZViiVs Two-Drug HIV Treatment Works Well - POZ
As is common in drug-switch studies, the side effects of Tivicay plus Edurant were greater than those of three- and four-drug regimens.
https://www.poz.com/article/viivs-twodrug-hiv-treatment-works
The nephroblastomatosis complex and its relationship to Wilms tumor<...
TY - JOUR. T1 - The nephroblastomatosis complex and its relationship to Wilms tumor. AU - Stone, Marshall M.. AU - Beaver, Bonnie L.. AU - Sun, Chen Chih J. AU - Laurance Hill, J.. PY - 1990. Y1 - 1990. N2 - Nephroblastomatosis (NB), a persistence of abnormal embryonal renal tissue beyond 36 weeks gestation, is often associated with Wilms tumor. The exact relationship of NB to the development of Wilms tumor is unclear. Four cases are presented that elucidate the entire morphological spectrum of this disease. Analyses of these cases suggest these conclusions: (1) the NB complex is a spectrum of lesions from benign multifocal nodular renal blastema, resembling residual nephrogenic zones of immature fetal kidney, to Wilms tumor; (2) infantile NB is a premalignant variant of Wilms tumor with a favorable outcome usually, when treated early; (3) neonatal nephromegaly requires a complete evaluation and follow-up imaging; persistence mandates biopsy; (4) second-look laparotomy is unnecessary ...
https://jhu.pure.elsevier.com/en/publications/the-nephroblastomatosis-complex-and-its-relationship-to-wilms-tum-5
PhD & MA Essays: Online homework systems plagiarism free!
This investigation revealed that persons in authority 2. 1. 2. 7 forging, tampering, altering or fabricating of school superintendents and the homework online systems explanation that interrupts the quotation. Did you hear the leaves into a computer analysis program for prevention and education do exist, if not. Respondents also wrote some of the bible and feminism, and her accountant. 4. In the writing carefully; pres ent study without needing to be an example for this, I think, to the book. Chap- ter 1 presents the results of other metadiscoursal features. They might also contribute to the illiterate locksmith is the language and then using those to create the present embracing instead what might be useful, it must be sensitive to foreign substances. Quelling this bad idea for further discussion, see linda brodkey s writing community engagement author bio allison carr is an example from another paragraph. When he was not seen by a researcher reads and writes itself in the first point of view. ...
https://web.ics.purdue.edu/~asub/?doc=online-homework-systems
Setback for Abiraterone Acetate in Recurrent Ovarian CancerSetback for Abiraterone Acetate in Recurrent Ovarian Cancer
Although one patient with recurrent ovarian cancer achieved complete response, the first trial of abiraterone conducted in ovarian cancer was halted early due to low response, according to results from the CORAL phase 2 trial.
http://www.targetedonc.com/conference/esmo-ovarian-2016/setback-for-abiraterone-acetate-in-recurrent-ovarian-cancer
Second-Look Surgery - procedure, tube, removal, pain, time, infection, medication, cellsSecond-Look Surgery - procedure, tube, removal, pain, time, infection, medication, cells
A second-look procedure is sometimes performed to determine if a cancer patient has responded successfully to a particular treatment. Examples of cancers that are assessed during second-look surgery are ovarian cancer and colorectal cancer. In many cases, before a round of chemotherapy and/or radiation therapy is started, a patient will undergo a surgical procedure called cytoreduction to reduce the size of a tumor. This debulking increases the sensitivity of the tumor and decreases the number of necessary treatment cycles. Following cytoreduction and chemotherapy, a second-look procedure may be necessary to determine if the area is cancer-free. An advantage to second-look surgery following cancer treatment is that if cancer is found, it may be removed during the procedure in some patients. In other cases, if a tumor cannot be entirely removed, the surgeon can debulk the tumor and improve the patients chances of responding to another cycle of chemotherapy. However, second-look surgery cannot ...
http://www.surgeryencyclopedia.com/Pa-St/Second-Look-Surgery.html
Researchers Investigate Dasatinib in Combination with Other Drugs for Advanced, Recurrent Ovarian Cancer | folypeberResearchers Investigate Dasatinib in Combination with Other Drugs for Advanced, Recurrent Ovarian Cancer | folypeber
Newswise ? Researchers at Moffitt Cancer Center and Duke University Medical Center have conducted a phase I trial of dasatinib, an oral SRC-family tyrosine kinase inhibitor, to determine the maximum tolerated dose when combined with paclitaxel and carboplatin to treat patients with advanced or recurrent ovarian cancer. They found that 150 mg daily in combination…
https://folypeber.wordpress.com/2012/11/16/researchers-investigate-dasatinib-in-combination-with-other-drugs-for-advanced-recurrent-ovarian-cancer/
HIV/TuberculosisHIV/Tuberculosis
At PSI, were focused on making it easier to prevent, identify and treat HIV/AIDS and TB. We bring consumer voices and perspectives to the disease response, supporting public and private health providers to better respond to the needs of their clients and patients.. Through activities including HIV self-testing, cyber-education, community coaching and pharmacy services, we are working to bring healthcare for HIV and TB closer to those who need it, pairing human connection with new technologies to reach everyone in need with services that speak to their reality.. ...
https://www.psi.org/practice-area/hiv-tb/
Pancreatic Cancer - An Introduction, with Dr. Andrew Ko | Cancer.NetPancreatic Cancer - An Introduction, with Dr. Andrew Ko | Cancer.Net
Dr. Ko: So, there are a couple of new combination chemotherapy regimens. that was developed in France, it was called [inaud.] and thats really an acronym of four different drugs combined together. And the results seen with that combination are better than any that was seen in any previous drug combination used in pancreatic cancer. So thats definitely been an important advance.. Its not a regimen that is appropriate for all patients, because as you might imagine when youre combining multiple drugs together in addition to better efficacy you also have more side effects and toxicity. So, that regiment does need to be used with some degree of caution. More recently theres been the approval of a drug called [inaud.], which when combined with [inaud.] shows a distinct survival benefit compared to [inaud.] by itself. So, just in these past few years we now have several new options and now were able to sequence these treatments, so a person might try something in the first line setting when ...
https://www.cancer.net/navigating-cancer-care/videos/cancer-research-news/pancreatic-cancer-%E2%80%93-introduction-dr-andrew-ko
HMM, YOU MIGHT SAY LONDONHMM, YOU MIGHT SAY LONDON
HMM, YOU MIGHT SAY LONDON IS (A BIT) AHEAD OF PARIS and THE RoE NUMBER OF JOBS IN FUNDED AI & DATA-DRIVEN STARTUPS SINCE 2014 9548 3676 922 798 556 632 445 207…
https://www.slideshare.net/jeanbaptiste.dumont/the-ai-rush-121047435/15-HMM_YOU_MIGHT_SAY_LONDON
AltretamineAltretamine
... (trade name Hexalen), also called hexamethylmelamine, is an antineoplastic agent. It was approved by the U.S. FDA ... Malik IA (2001). "Altretamine is an effective palliative therapy of patients with recurrent epithelial ovarian cancer". Jpn. J ... ISBN 978-0-7817-6879-5. Drugs.com: Altretamine Monograph Wiernik, P. H.; Yeap, B.; Vogl, S. E.; Kaplan, B. H.; Comis, R. L.; ... The precise mechanism by which altretamine exerts its anti-cancer effect is unknown but it is classified by MeSH as an ...
https://en.wikipedia.org/wiki/Altretamine
LofepramineLofepramine
Altretamine. Risk of severe drop in blood pressure upon standing. Analgesics (painkillers). Increased risk of ventricular ...
https://en.wikipedia.org/wiki/Lofepramine
TriethylenemelamineTriethylenemelamine
Altretamine Wong, Jeannette R.; Morton, Lindsay M.; Tucker, Margaret A.; Abramson, David H.; Seddon, Johanna M.; Sampson, ...
https://en.wikipedia.org/wiki/Triethylenemelamine
Eisai (company)Eisai (company)
This event brought Dacogen (decitabine), Aloxi (palonosetron), Hexalen (altretamine) for ovarian cancer, and the Gliadel Wafer ...
https://en.wikipedia.org/wiki/Eisai_(company)
MelamineMelamine
... is part of the core structure for a number of drugs including almitrine, altretamine, cyromazine, ethylhexyl triazone ...
https://en.wikipedia.org/wiki/Melamine
List of drugs: AlList of drugs: Al
... altretamine (INN) altumomab (INN) Alu-Cap Alu-Tab Aludrox aluminium clofibrate (INN) Alupent (Boehringer Ingelheim) Alustra ...
https://en.wikipedia.org/wiki/List_of_drugs:_Al
List of MeSH codes (D03)List of MeSH codes (D03)
... altretamine MeSH D03.383.931.190 - apazone MeSH D03.383.931.247 - atrazine MeSH D03.383.931.320 - ferrozine MeSH D03.383. ...
https://en.wikipedia.org/wiki/List_of_MeSH_codes_(D03)
Alkylating antineoplastic agentAlkylating antineoplastic agent
Procarbazine Altretamine Some sources explicitly exclude the triazenes (dacarbazine, mitozolomide, temozolomide) from the ...
https://en.wikipedia.org/wiki/Alkylating_antineoplastic_agent
ATC code L01ATC code L01
Rucaparib L01XK04 Talazoparib L01XK05 Veliparib L01XK06 Pamiparib L01XX01 Amsacrine L01XX02 Asparaginase L01XX03 Altretamine ...
https://en.wikipedia.org/wiki/ATC_code_L01
Index of oncology articlesIndex of oncology articles
... altretamine - aluminium sulfate - ALVAC-CEA vaccine - Amanita phalloides - Ambien - amelanotic melanoma - Ames, Bruce - ...
https://en.wikipedia.org/wiki/Index_of_oncology_articles
HemelHemel
... a rugby league club Trade name for altretamine Hemel (film), a 2012 Dutch film Armijn Hemel Mark Hemel (born 1966), Dutch ...
https://en.wikipedia.org/wiki/Hemel
Altretamine: MedlinePlus Drug InformationAltretamine: MedlinePlus Drug Information
Altretamine: learn about side effects, dosage, special precautions, and more on MedlinePlus ... Before taking altretamine,. *tell your doctor and pharmacist if you are allergic to altretamine, any other medications, or any ... You should not become pregnant or breast-feed while you are taking altretamine. If you become pregnant while taking altretamine ... Altretamine comes as a capsule to take by mouth. It is usually taken four times a day (a dose after each meal and a dose at ...
https://medlineplus.gov/druginfo/meds/a601200.html
A-Z Drug Index for Prescription and OTC MedicationsA-Z Drug Index for Prescription and OTC Medications
Altretamine is an antineoplastic alkylating agent, prescribed for certain types of cancer such as ovarian cancer. ...
https://www.medindia.net/doctors/drug_information/home.asp
Ovarian Cancer: Practice Essentials, Background, PathophysiologyOvarian Cancer: Practice Essentials, Background, Pathophysiology
Malignant lesions of the ovaries include primary lesions arising from normal structures within the ovary and secondary lesions from cancers arising elsewhere in the body. Primary lesions include epithelial ovarian carcinoma (70% of all ovarian malignancies), germ-cell tumors, sex-cord stromal tumors, and other more rare types.
https://www.medscape.com/answers/255771-194596/what-is-the-pathophysiology-of-ovarian-immature-teratoma
Long-term follow-up of a phase II trial of oral altretamine for consolidation of clinical complete remission in women with...Long-term follow-up of a phase II trial of oral altretamine for consolidation of clinical complete remission in women with...
Long-term follow-up of a phase II trial of oral altretamine for consolidation of clinical complete remission in women with ... Long-term follow-up of a phase II trial of oral altretamine for consolidation of clinical complete remission in women with ...
https://ijgc.bmj.com/content/14/2/224.alerts
Table 2 - Analysis of MarketScan Data for Immunosuppressive Conditions and Hospitalizations for Acute Respiratory Illness,...
These cookies allow us to count visits and traffic sources so we can measure and improve the performance of our site. They help us to know which pages are the most and least popular and see how visitors move around the site. All information these cookies collect is aggregated and therefore anonymous. If you do not allow these cookies we will not know when you have visited our site, and will not be able to monitor its performance. ...
https://wwwnc.cdc.gov/eid/article/26/8/19-1493-t2
Mi-Omega NF oral Interactions with Other MedicationMi-Omega NF oral Interactions with Other Medication
PYRIDOXINE/ALTRETAMINE Serious Interactions These medications may interact and cause very harmful effects. Consult your ...
https://www.webmd.com/drugs/2/drug-151055/mi-omega-nf-oral/details/list-interaction-medication
Biologics in Cervical Cancer Therapy in: Journal of the National Comprehensive Cancer Network Volume 8 Issue 12 (2010)Biologics in Cervical Cancer Therapy in: Journal of the National Comprehensive Cancer Network Volume 8 Issue 12 (2010)
... altretamine; 127F, topotecan; 127H, etoposide; 127K, gemcitabine) and the PFS from Gynecologic Oncology Group protocol 227-C ... altretamine; 127F, topotecan; 127H, etoposide; 127K, gemcitabine) and the PFS from Gynecologic Oncology Group protocol 227-C ... altretamine; 127F, topotecan; 127H, etoposide; 127K, gemcitabine) and the PFS from Gynecologic Oncology Group protocol 227-C ... altretamine; 127F, topotecan; 127H, etoposide; 127K, gemcitabine) and the PFS from Gynecologic Oncology Group protocol 227-C ...
https://jnccn.org/view/journals/jnccn/8/12/article-p1417.xml?rskey=QALzMV&result=7
Listing of Drugs Currently Regulated as New Drugs (The New Drugs List) - Canada.caListing of Drugs Currently Regulated as New Drugs (The New Drugs List) - Canada.ca
RxAssist - RXOUTREACH Patient Assist ProgramRxAssist - RXOUTREACH Patient Assist Program
A resource to help physicians, advocates, and patients access free medications through pharmaceutical company patient assistance programs.
https://www.rxassist.org/pap-info/company-detail?CmpId=132
CanMED: HCPCSCanMED: HCPCS
Fluad Quadrivalent (influenza virus vaccine quadrivalent, adjuvanted) dosing, indications, interactions, adverse effects, and...Fluad Quadrivalent (influenza virus vaccine quadrivalent, adjuvanted) dosing, indications, interactions, adverse effects, and...
altretamine. Serious - Use Alternative (1)altretamine decreases effects of influenza virus vaccine quadrivalent, adjuvanted by ... altretamine. altretamine decreases effects of influenza virus vaccine quadrivalent, adjuvanted by pharmacodynamic antagonism. ...
https://reference.medscape.com/drug/fluad-quadrivalent-influenza-virus-vaccine-quadrivalent-adjuvanted-4000082
Pediapred (prednisolone sodium phosphate) dose, indications, adverse effects, interactions... from PDR.netPediapred (prednisolone sodium phosphate) dose, indications, adverse effects, interactions... from PDR.net
Altretamine: (Minor) Concurrent use of altretamine with other agents which cause bone marrow or immune suppression such as ...
https://pdr.net/drug-summary/Pediapred-prednisolone-sodium-phosphate-2751
UNII - Q8BIH59O7HUNII - Q8BIH59O7H
ALTRETAMINE. *UNII: Q8BIH59O7H. *Formula: C9H18N6. *Preferred Substance Name: ALTRETAMINE. *InChIKey: UUVWYPNAQBNQJQ-UHFFFAOYSA ...
https://precision.fda.gov/uniisearch/srs/unii/Q8BIH59O7H
Annexes nationales de médicaments - ANORPAnnexes nationales de médicaments - ANORP
ATTENTION : Tous les résultats de la recherche seront tirés du « National Drug Schedules » du site Web en anglais.
https://www.napra.ca/fr/annexes-nationales-de-medicaments/?letter=b&print=
Proposition 65 List of Elabscience ChemicalsProposition 65 List of Elabscience Chemicals
Altretamine - 645-05-6 - Toxicity: developmental, male. *Amantadine hydrochloride - 665-66-7 - Toxicity: developmental ...
https://caslab.com/Proposition-65-List/?setCurrencyId=3
US Patent Application for ANTI-cMET ANTIBODY Patent Application (Application #20130109844 issued May 2, 2013) - Justia Patents...US Patent Application for ANTI-cMET ANTIBODY Patent Application (Application #20130109844 issued May 2, 2013) - Justia Patents...
... altretamine, trofosfamide, sulfofosfamide or ifosfamide; aziridines or imine-ethylenes such as thiotepa, triethylenamine or ...
https://patents.justia.com/patent/20130109844
Patent 2830806 Summary - Canadian Patents DatabasePatent 2830806 Summary - Canadian Patents Database
methylamelamines including altretamine, triethylenemelamine, trietylenephosphoramide, triethylenethiophosphoramide and ...
https://brevets-patents.ic.gc.ca/opic-cipo/cpd/eng/patent/2830806/summary.html
Buy Dasamaps 70mg Dasatinib Tablet Online at Wholesale PriceBuy Dasamaps 70mg Dasatinib Tablet Online at Wholesale Price
Buy Dasamaps 70mg Dasatinib Tablet at lowest price online. SHIPPING WORLDWIDE. Know Dasamaps 70mg cost, uses, generic alternative options with minimum prices from Oddway International Wholesaler, Exporter and Supplier
https://www.oddwayinternational.com/dasamaps-70mg-dasatinib-tablet/
National Ambulatory Medical Care Survey, 1997National Ambulatory Medical Care Survey, 1997
ALTRETAMINE 59624 DIATRIZOATE MEGLUMINE 59625 NITROGEN MUSTARD 59626 RIMEXOLONE 59627 MELATONIN 59628 DINITROCHLOROBENZENE ...
https://wonder.cdc.gov/wonder/sci_data/surveys/namcs/type_txt/namcs97.asp
Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated): Uses, Interactions, Mechanism of Action ...Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated): Uses, Interactions, Mechanism of Action ...
Altretamine. The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated) ... can be decreased when used in combination with Altretamine.. Amsacrine. The therapeutic efficacy of Influenza B virus B/ ...
https://go.drugbank.com/drugs/DB14385
Chemo Induced Nausea and Vomiting - Digital PharmDChemo Induced Nausea and Vomiting - Digital PharmD
Altretamine. Busulfan ≥ 4mg/day. Crisotinib. Cyclophosphamide ≥100 mg/m2/day. Estramustine ...
https://digitalpharmd.com/chemo-induced-nausea-and-vomiting/
Uncategorized - Superior Toxicology & WellnessUncategorized - Superior Toxicology & Wellness
Altretamine. $659.00. $450.00. Add to cart. * Sale! Aluminum Hydroxide. $659.00. $450.00. Add to cart ...
https://superiortoxicology.com/product-category/uncategorized/?product_added_to_cart=1958&quantity=1
Temoside 250 mg Capsule Buy Online at Lowest PriceTemoside 250 mg Capsule Buy Online at Lowest Price
Cantret : Altretamine 50 mg Capsules. Anti Cancer $169.00. $126.00. Brand: Natco Pharma Limited Add to cart ...
https://www.drugssquare.com/anti-cancer-drugs/temozolomide-temoside-250mg-capsules/
DOSING REGIMENS OF ANTI-ILT4 ANTIBODY OR ITS COMBINATION WITH ANTI-PD-1 ANTIBODY FOR TREATING CANCER - MERCK SHARP & DOHMEDOSING REGIMENS OF ANTI-ILT4 ANTIBODY OR ITS COMBINATION WITH ANTI-PD-1 ANTIBODY FOR TREATING CANCER - MERCK SHARP & DOHME
... altretamine, anhydrovinblastine, auristatin, bexarotene, bicalutamide, BMS 184476, 2,3,4,5,6-pentafluoro-N-(3-fluoro-4- ... altretamine, ifosfamide, procarbazine, mechlorethamine, streptozocin, thiotepa, and pharmaceutically acceptable salts thereof. ... altretamine, carmustine, bendamustine, busulfan, carboplatin, lomustine, cisplatin, chlorambucil, cyclophosphamide, dacarbazine ...
https://www.sumobrain.com/patents/wipo/Dosing-regimens-anti-ilt4-antibody/WO2022060767A1.html
Ovarian Cancer: Practice Essentials, Background, Pathophysiology
Malignant lesions of the ovaries include primary lesions arising from normal structures within the ovary and secondary lesions from cancers arising elsewhere in the body. Primary lesions include epithelial ovarian carcinoma (70% of all ovarian malignancies), germ-cell tumors, sex-cord stromal tumors, and other more rare types.
https://www.staging.medscape.com/answers/255771-194586/how-is-ovarian-cancer-treated
DeCSDeCS
use ALTRETAMINE to search HEXAMETHYLMELAMINE 1975-91. History Note:. 92; was HEXAMETHYLMELAMINE 1975-91 (see under TRIAZINES ...
https://decs.bvsalud.org/en/ths/resource/?id=30352
Table 2 - Analysis of MarketScan Data for Immunosuppressive Conditions and Hospitalizations for Acute Respiratory Illness,...
These cookies allow us to count visits and traffic sources so we can measure and improve the performance of our site. They help us to know which pages are the most and least popular and see how visitors move around the site. All information these cookies collect is aggregated and therefore anonymous. If you do not allow these cookies we will not know when you have visited our site, and will not be able to monitor its performance. ...
https://wwwnc-origin.cdc.gov/eid/article/26/8/19-1493-t2
Code System Concept
Product containing altretamine (medicinal product). Code System Preferred Concept Name. Product containing altretamine ( ...
https://phinvads.cdc.gov/vads/ViewCodeSystemConcept.action?oid=2.16.840.1.113883.6.96&code=69879000
Jesus and other religions | Saffronplanet.netJesus and other religions | Saffronplanet.net
... the physchiatric buy cefadroxil online of altretamine (vol d) of deafness in 8 folic percodans was 64 l. Healthcare fuses ...
http://saffronplanet.net/node/60?page=8
HexalenMedicationsCisplatinCapsuleIncludeDrugDoctorHexamethylmelamineCisplatinCapsulesOvarian cancerAntineoplastic AgentsMeenModerateSerumAllergicSevereLiverDoseBone marrow suppMedicinesEffectsCancerTreatmentCombinationPatientsArticlesResultsTimeUpdate
Hexalen2
Medications3
  • Altretamine is used to treat cancer of the ovaries (cancer that begins in the female reproductive organs where eggs are formed) that has not improved or that has worsened after treatment with other medications. (medlineplus.gov)
  • Altretamine is a medication that is in a class of medications called antineoplastic agents. (medlineplus.gov)
  • tell your doctor and pharmacist if you are allergic to altretamine, any other medications, or any of the ingredients in altretamine capsules. (medlineplus.gov)
Cisplatin1
  • Rejunuron Plus Injection 2 ml may interact with anti-cancer drugs (altretamine, cisplatin), fits medicines (phenytoin, phenobarbital), antibiotics (chloramphenicol), and medicines treating Parkinson's disease (levodopa). (apollopharmacy.in)
Capsule1
Include1
Drug1
  • Tous les résultats de la recherche seront tirés du « National Drug Schedules » du site Web en anglais. (napra.ca)
Doctor4
  • Your doctor will order certain tests before and during your treatment to check your body's response to altretamine. (medlineplus.gov)
  • Your doctor may adjust your dose of altretamine depending on your response to treatment and any side effects that you experience. (medlineplus.gov)
  • Do not stop taking altretamine without talking to your doctor. (medlineplus.gov)
  • If you become pregnant while taking altretamine, call your doctor. (medlineplus.gov)
Hexamethylmelamine3
  • Altretamine is an orally administered alkylating agent, formerly known as hexamethylmelamine, which is currently used as a secondary therapy for advanced ovarian carcinoma. (nih.gov)
  • Altretamine (hexamethylmelamine) in platinum-resistant and platinum-refractory ovarian cancer: a Gynecologic Oncology Group phase II trial. (nih.gov)
  • 15. A comparison of hexamethylmelamine (altretamine), cyclophosphamide, doxorubicin, and cisplatin (H-CAP) vs. cyclophosphamide, doxorubicin, and cisplatin (CAP) in advanced ovarian cancer. (nih.gov)
Cisplatin2
  • Altretamine is FDA approved as a single agent for the treatment of ovarian cancer that has stopped responding to previous therapy with a cisplatin and/or alkylating-based chemotherapy regimen. (thegiconnection.com)
  • Before using this product, tell your doctor or pharmacist of all prescription and nonprescription/herbal products you may use, especially of: altretamine, cisplatin, certain antibiotics (e.g., chloramphenicol), certain anti-seizure drugs (e.g., phenytoin), levodopa, other vitamin/nutritional supplements. (ndrugs.com)
Capsules1
  • tell your doctor and pharmacist if you are allergic to altretamine, any other medications, or any of the ingredients in altretamine capsules. (medlineplus.gov)
Ovarian cancer2
  • Altretamine is used for Ovarian Cancer and other conditions. (earthlinglifesciences.com)
  • Altretamine is used for the treatment, control, prevention, & improvement of the following diseases, conditions and symptoms like Ovarian Cancer. (earthlinglifesciences.com)
Antineoplastic Agents1
  • Altretamine is a medication that is in a class of medications called antineoplastic agents. (medlineplus.gov)
Meen1
  • Altretamine (al tret' a meen) is a synthetic, orally available alkylating agent belonging to the methylmelamine class of these agents. (nih.gov)
Moderate2
Serum2
  • Altretamine therapy has been associated with low rates of serum enzyme elevations during therapy and with rare instances of acute, clinically apparent injury. (nih.gov)
  • Altretamine therapy is associated with a low rate of serum enzyme elevations, but these are generally mild and self limited, not requiring dose adjustment. (nih.gov)
Allergic1
  • Tell your doctor if you have ever had any unusual or allergic reaction to Altretamine or any other medicines. (anticancercure.com)
Severe2
Liver4
  • Rare instances of clinically apparent acute liver injury attributed to altretamine have been reported, but the clinical features have not been characterized. (nih.gov)
  • The cause of the idiosyncratic liver injury associated with altretamine use is probably related to a hypersensitivity reaction to a hepatic metabolite of the drug, which is extensively metabolized by the liver. (nih.gov)
  • Liver injury is very rare after altretamine therapy. (nih.gov)
  • In situations of acute liver injury after altretamine use, rechallenge should be avoided. (nih.gov)
Dose2
  • Your doctor may adjust your dose of altretamine depending on your response to treatment and any side effects that you experience. (medlineplus.gov)
  • For best results, it is important to receive each scheduled dose of Altretamine medication as instructed. (anticancercure.com)
Bone marrow supp1
  • Altretamine shares common side effects with other alkylating agents such as nausea, vomiting, diarrhea, alopecia, bone marrow suppression, peripheral neuropathy and rash. (nih.gov)
Medicines1
  • Altretamine belongs to the general group of medicines called antineoplastics. (anticancercure.com)
Effects10
  • Altretamine may cause side effects. (medlineplus.gov)
  • Most side effects from Altretamine are common, but a few can be serious. (anticancercure.com)
  • These are not all the possible side effects of Altretamine cancer medicine. (anticancercure.com)
  • To learn more about possible side effects of Cantret (Altretamine), read the drug label or package insert or talk to your health care provider. (anticancercure.com)
  • altretamine decreases effects of influenza virus vaccine quadrivalent, adjuvanted by pharmacodynamic antagonism. (medscape.com)
  • Altretamine produces anti-cancer effects through several possible mechanisms. (thegiconnection.com)
  • What are the most common (occur in 30% or more of patients) side effects of treatment with altretamine? (thegiconnection.com)
  • What are the less common (occur in 10% to 29% of patients) side effects of treatment with altretamine? (thegiconnection.com)
  • Altretamine: minor in the numerous adverse effects, oral candidiasis. (michiganslipandfalllawyers.com)
  • Polynerv™ 1000 tablet may reduce the effects of levodopa and altretamine. (svmoregroup.com)
Cancer1
  • Altretamine is used to treat cancer of the ovaries (cancer that begins in the female reproductive organs where eggs are formed) that has not improved or that has worsened after treatment with other medications. (medlineplus.gov)
Treatment1
  • Your doctor will order certain tests before and during your treatment to check your body's response to altretamine. (medlineplus.gov)
Combination2
  • The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated) can be decreased when used in combination with Altretamine. (drugbank.com)
  • The therapeutic efficacy of Palifermin can be decreased when used in combination with Altretamine. (drugbank.com)
Patients2
  • Typically, patients are instructed to take altretamine in divided doses following a meal and at bedtime. (thegiconnection.com)
  • Patients will usually have scheduled meetings with their healthcare provider while they are being treated with altretamine. (thegiconnection.com)
Articles1
  • Altretamine is part of WikiMD's free ^articles! (wikimd.org)
Results1
  • The DNA damage caused by altretamine results in inhibition of cellular growth and/or cellular death. (thegiconnection.com)
Time1
Update1